Regulatory Status Summary (as of July 29, 2026) Category 2 restricted status: Removed (April 2026) FDA approval: None USP/NF monograph: None 503A Bulks List: PCAC recommended inclusion (July 2324, 2026, nonbinding)
ISSN 1516-635X DersjantLi, Y
Summary Gala GLP-1 is a prescription telehealth platform operated by AI Coaching, Inc., designed to connect patients with licensed healthcare providers for GLP-1 and GLP-1/GIP weight management consultations across all 50 states
Tirzepatide: A dual GLP-1 and GIP receptor agonist that enhances insulin secretion, reduces hunger, and improves metabolic function, marketed under brand names like Mounjaro and Zepbound
How Many People Are on GLP-1 Drugs and Where It's Headed GLP-1 receptor agonists originally developed to manage type 2 diabetes became a mainstream weight-loss category after Ozempic's consumer breakthrough in 2023